Best example ( I sometimes think its PHs wet dream) is Kite...

Best example ( I sometimes think its PHs wet dream) is Kite Pharma, IMU is just following the same trajectory, below is good read

Clinical Trials and Product Development:

• Kite Pharma developed Yescarta, a CAR-T therapy for cancer, which, like Imugene's HER-Vaxx and Azer-cel, was focused on highly specific immuno-oncology applications. Yescarta received FDA approval in 2017 after clinical trials demonstrated significant improvements in cancer survival rates.
• Imugene’s pipeline includes HER-Vaxx (in Phase II/III for HER2-positive gastric cancer) and Azer-cel, an allogeneic CAR-T therapy, which parallels the kind of clinical advancements seen with Kite's portfolio.

Capital Raises:

• Kite raised substantial capital before its acquisition, similar to Imugene’s $95 million raise. This capital was used to fund late-stage clinical trials and regulatory filings for Yescarta. Imugene is similarly raising funds to push its immunotherapy programs, including HER-Vaxx and Azer-cel, through advanced clinical phases.

Valuation and Market Sentiment:

• Kite Pharma's valuation grew as it achieved key clinical milestones, much like what Imugene might expect if its trials continue to show positive results. Before its acquisition by Gilead Sciences in 2017, Kite Pharma had reached a valuation of $11.9 billion. Its stock price surged from around $45 per share to nearly $180 per share in a short period, especially after FDA approval for Yescarta

Outcome and Takeover:

• Kite Pharma was acquired by Gilead Sciences for $11.9 billion in 2017. This acquisition was driven by the success of Yescarta and its potential to dominate the CAR-T therapy market. Kite’s final share price was approximately $180 per share before the acquisition.
• For Imugene, a successful outcome for products like HER-Vaxx and Azer-cel could result in a similar trajectory, with larger pharmaceutical companies possibly looking to acquire Imugene if these products continue to show promise in clinical trials.

If Imugene's Azer-cel progresses through clinical trials and reaches approval for NHL, the company could see a significant increase in valuation, similar to Kite Pharma's journey. In the event of positive trial outcomes, Imugene could become a prime target for acquisition, potentially pushing its valuation into the $1 billion+ range. Its share price could rise significantly as it moves closer to pivotal trials and, eventually, commercialization, with a potential future share price of $1 or more within the next 5 years, contingent on clinical success and imagine we have more than 3 products on clinical trails, potentially we should be a dollar company sooner...